Trial reportNature communications2025
A prospective trial for breast cancer diagnosis by canine odorology.
Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04217109 (KDOG1), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
KDOG1 :Transcutaneous Breast Cancer Diagnosis by Canine Odorology
Who cites it
1 citing paper in PubMed.
- Preliminary Descriptive Study on the Conservation of Human Sweat Odor: Impact of Storage Temperature and Duration on the Stability of Volatile Organic Compounds in Sorbent Samples.International journal of analytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is a major health concern affecting millions of women worldwide. This study (NCT04217109) explores canine odorology as a method for identifying BC using patient sweat samples. To collect the sweat samples, the night before biopsies, a compress is applied to the affected breast and the sample is subsequently presented to two trained dogs during the training or testing sessions. A positive cancer detection is indicated if a dog halts in front of the compress. A total of 181 patients participate, 107 with breast cancer (82 invasive and 25 in situ) and 74 with benign lesions. Sensitivity (Se) is 68% and specificity (Sp) 27% for a single randomly selected dog. When at least one dog marks a sample, Se rises to 80.4% but Sp drops to 21.6%. If both dogs mark it, Se is 48.6% and Sp 45.9%. Results show limited ability to distinguish benign from malignant lesions. Dogs perform best with mixed samples but struggle when all are negative, with variable responses between dogs. Identifying BC-specific volatile compounds may improve accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.